Codexis, Inc. (NASDAQ:CDXS) Stock Has Consensus Price Target of $6.00

Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has been given a consensus rating of “Hold” by the five brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $6.00.

Several equities research analysts recently weighed in on the stock. Weiss Ratings raised shares of Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 23rd. Piper Sandler lowered their target price on shares of Codexis from $9.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, August 17th. Stephens restated an “overweight” rating and set a $5.00 price target on shares of Codexis in a research report on Monday, November 16th. Wall Street Zen raised shares of Codexis from a “sell” rating to a “hold” rating in a research note on Saturday, November 14th. Finally, Benchmark reaffirmed a “hold” rating on shares of Codexis in a research note on Thursday, August 20th.

Read Our Latest Stock Report on CDXS

Codexis Trading Down 5.7%

NASDAQ:CDXS opened at $0.99 on Monday. Codexis has a 12-month low of $0.90 and a 12-month high of $2.98. The firm has a market capitalization of $108.50 million, a P/E ratio of -4.95 and a beta of 2.38. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.81 and a quick ratio of 2.99. The business has a 50 day simple moving average of $1.25 and a 200 day simple moving average of $1.77.

Codexis (NASDAQ:CDXS – Get Free Report) last issued its earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.02. Codexis had a negative return on equity of 43.24% and a negative net margin of 21.77%. The firm had revenue of $19.26 million for the quarter, compared to analyst estimates of $18.72 million. Equities research analysts predict that Codexis will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its holdings in shares of Codexis by 93.3% in the third quarter. Goldman Sachs Group Inc. now owns 840,866 shares of the biotechnology company’s stock valued at $1,169,000 after buying an additional 405,942 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Codexis during the 3rd quarter worth $160,000. Private Advisor Group LLC bought a new stake in shares of Codexis during the 3rd quarter worth $1,677,000. Aberdeen Group plc grew its holdings in shares of Codexis by 59.5% in the 3rd quarter. Aberdeen Group plc now owns 10,797,702 shares of the biotechnology company’s stock worth $15,009,000 after acquiring an additional 4,027,748 shares during the last quarter. Finally, Prescott Group Capital Management L.L.C. acquired a new position in shares of Codexis in the 3rd quarter worth $556,000. 78.54% of the stock is owned by institutional investors and hedge funds.

Codexis Company Profile

(Get Free Report)

Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.

Featured Stories

Analyst Recommendations for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.